Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | Effectiveness of hydroxyurea in pediatric SCD in the real world

Subarna Chakravorty • 2 Apr 2019
BSH 2019
Non-Malignant Sickle Cell Disease Hydroxyurea

Subarna Chakravorty, MBBS, FRCPath, MRCPCH, PhD, King’s College Hospital NHS Foundation Trust, London, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. She discusses the effectiveness of hydroxyurea in children with sickle cell disease (SCD) via analysis of dose-response metrics in a large birth cohort in a tertiary SCD center.

More from Subarna Chakravorty

2:57
Global initiatives in SCD and the role of the Lancet Commission
Subarna Chakravorty • 26 Oct 2023
1:17
Overcoming the financial challenge of gene therapy for SCD
Subarna Chakravorty • 26 Oct 2023
2:23
The current landscape of thalassemia treatment
Subarna Chakravorty • 26 Oct 2023
5:16
Disease-modifying and curative SCD treatment updates from ASCAT 2023
Subarna Chakravorty • 26 Oct 2023

Related Videos

1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
0:59
HdxSim: a clinical decision support tool for model-informed precision dosing of hydroxyurea in SCD
Alexandra Power-Hays • 11 Dec 2023
1:54
CAR-Tregs hold potential for the treatment of autoimmune disease
Matteo Doglio • 16 Feb 2024
The content of VJHemOnc is intended for healthcare professionals